Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q1 2023 · 10-Q
Revenue$19.14M$19.14M−13.9% vs Q1 2022 Net Income-$66.68M-$66.68MN/M vs Q1 2022 EPS Diluted-$1.53-$1.53N/M vs Q1 2022 Operating Income-$66,157,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
Free Cash Flowderived-$85,736,000N/M Margins · derivedOperating margin-345.7%−23.8 pt vs Q1 2022
Net margin-348.4%−3.1 pt vs Q1 2022
ended Mar 31, 2023 · filed May 3, 2023 · 33 d after period end